388 related articles for article (PubMed ID: 11956091)
1. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
2. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
3. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
[TBL] [Abstract][Full Text] [Related]
4. CPI-0004Na, a new doxorubicin prodrug, reduces growth of 3LL-H61 carcinoma lung metastases in C57BI/6 mice.
Dasnois L; Lebtahi K; Abarca-Quinones J; Havaux N; Dupont S; Dubois V; Trouet A
J Exp Ther Oncol; 2004 Jul; 4(2):167-9. PubMed ID: 15500012
[TBL] [Abstract][Full Text] [Related]
5. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Ravel D; Dubois V; Quinonero J; Meyer-Losic F; Delord J; Rochaix P; Nicolazzi C; Ribes F; Mazerolles C; Assouly E; Vialatte K; Hor I; Kearsey J; Trouet A
Clin Cancer Res; 2008 Feb; 14(4):1258-65. PubMed ID: 18281561
[TBL] [Abstract][Full Text] [Related]
6. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
8. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
[TBL] [Abstract][Full Text] [Related]
9. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
[TBL] [Abstract][Full Text] [Related]
10. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
11. Thimet oligopeptidase (EC 3.4.24.15) activates CPI-0004Na, an extracellularly tumour-activated prodrug of doxorubicin.
Dubois V; Nieder M; Collot F; Negrouk A; Nguyen TT; Gangwar S; Reitz B; Wattiez R; Dasnois L; Trouet A
Eur J Cancer; 2006 Nov; 42(17):3049-56. PubMed ID: 16644202
[TBL] [Abstract][Full Text] [Related]
12. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
[TBL] [Abstract][Full Text] [Related]
13. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
14. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
15. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
[TBL] [Abstract][Full Text] [Related]
16. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
DeFeo-Jones D; Garsky VM; Wong BK; Feng DM; Bolyar T; Haskell K; Kiefer DM; Leander K; McAvoy E; Lumma P; Wai J; Senderak ET; Motzel SL; Keenan K; Van Zwieten M; Lin JH; Freidinger R; Huff J; Oliff A; Jones RE
Nat Med; 2000 Nov; 6(11):1248-52. PubMed ID: 11062536
[TBL] [Abstract][Full Text] [Related]
17. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine.
Gupta A; Miki K; Xu M; Yamamoto N; Moossa AR; Hoffman RM
Anticancer Res; 2003; 23(2B):1181-8. PubMed ID: 12820369
[TBL] [Abstract][Full Text] [Related]
18. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
20. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.
Hu Z; Jiang X; Albright CF; Graciani N; Yue E; Zhang M; Zhang SY; Bruckner R; Diamond M; Dowling R; Rafalski M; Yeleswaram S; Trainor GL; Seitz SP; Han W
Bioorg Med Chem Lett; 2010 Feb; 20(3):853-6. PubMed ID: 20060717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
